KPV vs TB-500
Both KPV and TB-500 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →Side-by-Side
| Attribute | KPV | TB-500 |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) |
| Typical Dose | 200–500 mcg orally or topical (research only) | 2 mg twice weekly (subcutaneous) |
| Clinics Indexed | 26 | 183 |
| Categories | anti-inflammatory, gut-health, skin | recovery, anti-inflammatory |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.